Skip to content

Released Mar 18, 2019, before the open

10-K filed Mar 18, 2019, 77 days after period end · 0001144204-19-014464

Q4 2018 · 10-K
Revenue$27.02Mderived+527.6% vs Q4 2017+3,975.1% vs Q3 2018
Net Income-$5.43MN/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.40no prior Q4 2017 on fileN/M vs Q3 2018
Operating Income-$3,672,000N/M
Operating Cash Flowderived-$4,004,000N/M
Free Cash Flowderived-$4,192,000N/M
Margins · derived
Operating margin-13.6%+209.0 pt vs Q4 2017
Net margin-20.1%+288.9 pt vs Q4 2017

What the release said

The release

Same quarter

MetricQ4 2018Q4 2017derived from reported figuresQ4 2016derived from reported figuresQ4 2015derived from reported figures
Revenue$27.02M$4.31M$2.08M$0.00
Net Income-$5.43M-$13.31M-$2.62M$72.90M
EPS Diluted-$0.40———

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR